Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jinglan Zhou is active.

Publication


Featured researches published by Jinglan Zhou.


Proceedings of the National Academy of Sciences of the United States of America | 2009

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Fredrick Van Goor; Sabine Hadida; Peter D. J. Grootenhuis; B. Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani K. Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason Mccartney; Vijayalaksmi Arumugam; Caroline J. Decker; Jennifer Yang; Christopher Young; Eric R. Olson; Jeffery J. Wine; Raymond A. Frizzell; Melissa A. Ashlock; Paul Negulescu

Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung. Most CF mutations either reduce the number of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both. There are currently no approved therapies that target CFTR. Here we describe the in vitro pharmacology of VX-770, an orally bioavailable CFTR potentiator in clinical development for the treatment of CF. In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl− secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈10-fold, to ≈50% of that observed in HBE isolated from individuals without CF. Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures. These results support the hypothesis that pharmacological agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.


Journal of Organic Chemistry | 2015

Synthesis of Fused Bicyclic Piperidines: Potential Bioactive Templates for Medicinal Chemistry

Jinglan Zhou; Erica L. Campbell-Conroy; Alina Silina; Johnny Uy; Fabrice Jean Denis Pierre; Dennis James Hurley; Nicole Hilgraf; Bryan A. Frieman; Michael Paul Deninno

An array of six pyridyl-substituted fused bicyclic piperidines was prepared as novel cores for medicinal chemistry. For maximum diversity, the size of the fused ring varied from three to six atoms and contained up to two oxygen atoms. The pyridine ring was incorporated to improve physicochemical properties and to challenge the robustness of the chemistry. The presence of the pyridine did interfere with our initial approaches to these molecules, and in several instances, a blocking strategy had to be employed. These new scaffolds possess high sp3 character and may prove useful in multiple medicinal chemistry applications.


Tetrahedron Letters | 1999

Solid-phase synthesis of potential aspartic acid protease inhibitors containing a hydroxyethylamine isostere

Jinglan Zhou; Andreas Termin; Melissa Wayland; Christine M. Tarby

Abstract A series of 1,3-diamino-2-propanol derivatives have been synthesized on solid phase as potential aspartic acid protease inhibitors. The developed methodology allows the incorporation of either an alkyl group or H at the R 2 site of hydroxyethylamine isostere.


Archive | 2005

Modulators of ATP-binding cassette transporters

Urvi Sheth; Lev T. D. Fanning; Mehdi Numa; Hayley Binch; Dennis James Hurley; Jinglan Zhou; Sara S. Hadida Ruah; Anna Hazlewood; Alina Silina; Rajendran Vairagoundar; Fredrick Van Goor; Peter D. J. Grootenhuis; Martyn Botfield


Archive | 2013

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

Sarah Hadida-Ruah; Frederick Van Goor; Mark Miller; Jason Mccartney; Jinglan Zhou; Vijayalaksmi Arumugam


Archive | 2009

Pyridyl derivatives as CFTR modulators

Sara Sabina Hadida-Ruah; Mark Miller; Jinglan Zhou; Brian Bear; Peter D. J. Grootenhuis


Archive | 2006

HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Ruah Sarah S. Hadida; Matthew Hamilton; Mark Miller; Peter D. J. Grootenhuis; Brian Bear; Jason Mccarthy; Jinglan Zhou


Archive | 2009

Heteroaryl derivatives as cftr modulators

Sara S. Hadida Ruah; Mark Miller; Jinglan Zhou; Brian Bear


Archive | 2007

Indole derivatives as CFTR modulators

Sara S. Hadida Ruah; Peter D. J. Grootenhuis; Fredrick Van Goor; Jinglan Zhou; Brian Bear; Mark Miller; Jason Mccartney; Mehdi Numa


Archive | 2008

Modulators of CFTR

Sara S. Hadida Ruah; Mark Miller; Brian Bear; Jinglan Zhou; Jason Mccartney; Peter D. J. Grootenhuis

Collaboration


Dive into the Jinglan Zhou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark Miller

Vertex Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Brian Bear

Vertex Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Urvi Sheth

Vertex Pharmaceuticals

View shared research outputs
Researchain Logo
Decentralizing Knowledge